Non-Coding RNA in Cholangiocarcinoma: An Update
Frontiers in Bioscience-Landmark · 2023
DOI: 10.31083/j.fbl2808173 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Bioscience-Landmark, 2023. Verfasst von Jiehan Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Hepatopancreatobiliary Surgery, Second Affiliated Hospital of Harbin Medical University, 150086 Harbin, Heilongjiang, China. Hauptthemen laut MEDLINE: Cholangiocarcinoma, MicroRNAs, RNA, Long Noncoding, Bile Duct Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 136 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hong Kong Scholars Program, National Natural Science Foundation of China, Excellent Young Scientists Project of Natural Science Foundation of Heilongjiang Province.
Abstract (Originalsprache)
Cholangiocarcinoma (CCA) is one of the most common tumors with high malignancy. Its incidence is increasing year by year, and it is insidious and easily metastasized, and most patients are already in advanced stages when they are diagnosed. Surgery is an essential treatment for CCA, but the 5-year survival rate is still unsatisfactory due to the low early diagnosis rate and high malignancy of CCA. Therefore, exploring the molecular mechanisms of CCA to find reliable biomarkers and effective therapeutic targets is essential to improve the early diagnosis and survival rate of CCA. Non-coding RNA (ncRNA) is a class of RNA without protein-coding ability, mainly including microRNA (miRNA), long non-coding RNA (lncRNA), and circular RNA (circRNA). In recent years, numerous pieces of evidence have shown that aberrantly expressed ncRNAs can regulate the occurrence and development of CCA through various mechanisms such as mediating epigenetic, sponge miRNAs regulating the expression of target genes and participating in regulating cancer-related signaling pathways, which provides new approaches and ideas for early diagnosis, prognosis assessment and therapeutic targeting of CCA. In this paper, we review the molecular mechanisms of lncRNAs and circRNAs regulating the progression of CCA in recent years and discuss their potential clinical value in CCA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hepatopancreatobiliary Surgery, Second Affiliated Hospital of Harbin Medical University, 150086 Harbin, Heilongjiang, China.
- Key Laboratory of Functional and Clinical Translational Medicine, Fujian Province University, Xiamen Medical College, 361008 Xiamen, Fujian, China.
- Jiangsu Province Engineering Research Center of Tumor Targeted Nano Diagnostic and Therapeutic Materials, Yancheng Teachers University, 224002 Yancheng, Jiangsu, China.
- Department of Pathology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
- Key Laboratory of Myocardial Ischemia, Ministry of Education, Harbin Medical University, 150088 Harbin, Heilongjiang, China.
Förderung
- Hong Kong Scholars Program
- National Natural Science Foundation of China
- Excellent Young Scientists Project of Natural Science Foundation of Heilongjiang Province
- Special Project of China Postdoctoral Science Foundation
- Special Project of Heilongjiang Postdoctoral Science Foundation
- China Postdoctoral Science Foundation
- Heilongjiang Postdoctoral Science Foundation
- The Fundamental Research Funds for the Heilongjiang Provincial Universities
Zitieren
APA
Li, J., Bao, H., Huang, Z., Liang, Z., Lin, N., Ni, C., & Xu, Y. (2023). Non-Coding RNA in Cholangiocarcinoma: An Update. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/j.fbl2808173
Vancouver
Li J, Bao H, Huang Z, Liang Z, Lin N, Ni C, et al. Non-Coding RNA in Cholangiocarcinoma: An Update. Frontiers in Bioscience-Landmark. 2023. doi:10.31083/j.fbl2808173
BibTeX
@article{Li2023,
author = {Li, Jiehan and Bao, Haolin and Huang, Ziyue and Liang, Zixin and Lin, Ning and Ni, Chunjie and Xu, Yi},
title = {Non-Coding RNA in Cholangiocarcinoma: An Update},
journal = {Frontiers in Bioscience-Landmark},
year = {2023},
doi = {10.31083/j.fbl2808173}
}
EUVIMED